Literature DB >> 23889119

Primary Gleason pattern in biopsy Gleason score 7 is predictive of adverse histopathological features and biochemical failure following radical prostatectomy.

Kasper Drimer Berg1, Martin Andreas Røder, Klaus Brasso, Ben Vainer, Peter Iversen.   

Abstract

OBJECTIVE: The aim of this study was to analyse whether primary Gleason pattern in biopsy Gleason score (GS) 7 predicted adverse histopathological features and had an impact on the risk of biochemical failure in a consecutive series of patients undergoing radical prostatectomy (RP).
MATERIAL AND METHODS: Between 2006 and 2010, 441 patients with biopsy GS 7 underwent RP at Rigshospitalet, Copenhagen, Denmark. Favourable histopathological features were defined as pT2 margin-negative cancer, RP specimen GS ≤ 3+4 and no lymph-node metastasis. Adverse histopathological features were defined as advanced pT3/4 cancer or pT2 margin-positive cancer and/or RP specimen GS ≥ 4+3 and/or positive lymph nodes. Biochemical failure was defined as the first prostate-specific antigen (PSA) ≥ 0.2 ng/ml.
RESULTS: A total of 344 patients (78.0%) had GS 3+4 in biopsies, while 97 patients (22.0%) had GS 4+3. No difference in age, PSA, percentage of biopsies with cancer, clinical tumour stage or volume on transrectal ultrasonography was found. Primary Gleason pattern 4 was associated with worse pathological stage (p = 0.049). On multivariate analysis, primary Gleason pattern 4 (p < 0.0001), cT stage (p = 0.024), PSA (p < 0.0001) and age (p = 0.009) predicted adverse histopathological features. In univariate analysis, Gleason score 3+4 had a significantly lower biochemical failure rate compared with Gleason score 4+3 (p = 0.0035). PSA (p < 0.0001), primary Gleason pattern 4 (p = 0.001) and percentage of biopsies with cancer (p = 0.02) were independently associated with risk of biochemical failure.
CONCLUSIONS: In biopsies with GS 7, a primary Gleason pattern 4 was associated with significantly elevated risk of adverse histopathological features and biochemical failure compared to pattern 3 in patients undergoing RP. This study underlines the heterogeneity of biopsy GS 7.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23889119     DOI: 10.3109/21681805.2013.821628

Source DB:  PubMed          Journal:  Scand J Urol        ISSN: 2168-1805            Impact factor:   1.612


  4 in total

1.  Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence.

Authors:  Qi Long; Jianpeng Xu; Adeboye O Osunkoya; Soma Sannigrahi; Brent A Johnson; Wei Zhou; Theresa Gillespie; Jong Y Park; Robert K Nam; Linda Sugar; Aleksandra Stanimirovic; Arun K Seth; John A Petros; Carlos S Moreno
Journal:  Cancer Res       Date:  2014-04-08       Impact factor: 12.701

2.  Final Gleason score prediction using discriminant analysis and support vector machine based on preoperative multiparametric MR imaging of prostate cancer at 3T.

Authors:  Fusun Citak-Er; Metin Vural; Omer Acar; Tarik Esen; Aslihan Onay; Esin Ozturk-Isik
Journal:  Biomed Res Int       Date:  2014-12-02       Impact factor: 3.411

3.  Transcriptome Analysis Identifies Piwi-Interacting RNAs as Prognostic Markers for Recurrence of Prostate Cancer.

Authors:  Yuanli Zuo; Yu Liang; Jiting Zhang; Yingyi Hao; Menglong Li; Zhining Wen; Yun Zhao
Journal:  Front Genet       Date:  2019-10-22       Impact factor: 4.599

4.  A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists.

Authors:  Lina Maria Carmona Echeverria; Aiman Haider; Alex Freeman; Urszula Stopka-Farooqui; Avi Rosenfeld; Benjamin S Simpson; Yipeng Hu; David Hawkes; Hayley Pye; Susan Heavey; Vasilis Stavrinides; Joseph M Norris; Ahmed El-Shater Bosaily; Cristina Cardona Barrena; Simon Bott; Louise Brown; Nick Burns-Cox; Tim Dudderidge; Alastair Henderson; Richard Hindley; Richard Kaplan; Alex Kirkham; Robert Oldroyd; Maneesh Ghei; Raj Persad; Shonit Punwani; Derek Rosario; Iqbal Shergill; Mathias Winkler; Hashim U Ahmed; Mark Emberton; Hayley C Whitaker
Journal:  Sci Rep       Date:  2020-10-14       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.